Risto-cel shows efficacy in Sickle Cell Disease trial

Beam Therapeutics published Phase 1/2 BEACON trial results in The New England Journal of Medicine reporting that risto-cel had an acceptable safety profile consistent with myeloablative conditioning and that patients had improved hemolysis markers and no investigator-reported severe vaso-occlusive crises after engraftment.

Beam Therapeutics announced publication of Phase 1/2 BEACON trial data in The New England Journal of Medicine on ristoglogene autogetemcel, or risto-cel, formerly called BEAM-101. The trial evaluated risto-cel as an investigational autologous cell therapy for people with sickle cell disease and severe vaso-occlusive crises. The reported data described an acceptable safety profile consistent with myeloablative conditioning and characterized the efficacy as promising. The publication highlights improvements in hemolysis parameters, resolution of anemia, and no investigator-reported severe vaso-occlusive crises following engraftment. Key results: - Patients achieved rapid and robust bone marrow reconstitution after risto-cel treatment. - No patients experienced any investigator-reported severe vaso-occlusive crises following engraftment. - Mean hemoglobin F levels rose above 60% and there was a mean durable reduction in hemoglobin S to below 40%. - Key markers of hemolysis normalized or improved in all patients and sickling parameters decreased to levels comparable to those seen in sickle cell trait. - The safety profile reported was consistent with busulfan conditioning, autologous hematopoietic stem cell transplantation, and underlying sickle cell disease. Summary: The NEJM publication reports clinical improvements in hematologic markers, bone marrow reconstitution, and absence of investigator-reported severe vaso-occlusive crises after engraftment in the BEACON trial cohort. Undetermined at this time.